Pyxis Oncology Reports Shareholder Vote

TL;DR

Pyxis Oncology held a shareholder vote on June 11th, details to follow.

AI Summary

Pyxis Oncology, Inc. filed an 8-K on June 12, 2024, reporting on a matter submitted to a vote of its security holders on June 11, 2024. The filing does not disclose the specific outcome or details of the vote, only that it occurred.

Why It Matters

This filing indicates a shareholder vote took place, which could relate to significant corporate actions or governance changes that may impact the company's future direction.

Risk Assessment

Risk Level: medium — The lack of specific details about the shareholder vote introduces uncertainty regarding potential corporate changes.

Key Players & Entities

• Pyxis Oncology, Inc. (company) — Registrant
• June 11, 2024 (date) — Date of earliest event reported
• June 12, 2024 (date) — Date of report
• 321 Harrison Avenue, Boston, Massachusetts 02118 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share PYXS The Nasdaq Global Se

Filing Documents

• pyxs-20240611.htm (8-K) — 59KB
• 0000950170-24-072467.txt ( ) — 174KB
• pyxs-20240611.xsd (EX-101.SCH) — 25KB
• pyxs-20240611_htm.xml (XML) — 5KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 11, 2024, Pyxis Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders at 10:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the "Annual Meeting"). As of April 18, 2024, the Company's record date, there were a total of 58,876,390 shares of common stock outstanding and entitled to vote at the Annual Meeting. At the beginning of the Annual Meeting, 42,336,191 shares of common stock were present virtually, in person or by proxy, and, therefore, a quorum was present. Two items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below. Proposal One: Election of Dr. Santhosh Palani, Ph.D., CFA as Class I Director and Mr. John Flavin, Dr. Lara Sullivan, M.D. and Dr. Jakob Dupont, M.D. as Class III Directors Dr. Santhosh Palani, Ph.D., CFA was elected to serve as a Class I director to hold office until the Company's 2025 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Dr. Santhosh Palani, Ph.D., CFA 28,241,400 93,674 14,001,117 Mr. John Flavin, Dr. Lara Sullivan, M.D. and Dr. Jakob Dupont, M.D. were elected to serve as Class III directors to hold office until the Company's 2027 Annual Meeting of Stockholders and until the election and qualification of their successors. Votes were cast as follows: Name of Director Nominee For Withheld Broker Non-Votes Mr. John Flavin 21,045,395 7,287,768 14,003,028 Dr. Lara Sullivan, M.D. 24,369,861 3,963,302 14,003,028 Dr. Jakob Dupont, M.D. 28,220,452 114,622 14,001,117 Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registere

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pyxis Oncology, Inc. Date: June 11, 2024 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer